Prediction of human metabolism of FK3453 by aldehyde oxidase using chimeric mice transplanted with human or rat hepatocytes

Drug Metabolism and Disposition

Volumn 40, Issue 1, 2012, Pages 76-82

  Sanoh, Seigo ^a   Nozaki, Kazuyoshi ^b   Murai, Hidetsugu ^b   Terashita, Shigeyuki ^b   Teramura, Toshio ^b   Ohta, Shigeru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2 AMINO 4 PHENYLPYRIMIDINE 5 YL) 2 ISOPROPYLPYRIDAZIN 3(2H) ONE; 6 (2 AMINO 6 OXO 4 PHENYL 1,6 DIHYDROPYRIMIDIN 5 YL) 2 ISOPROPYLPYRIDAZIN 3(2H) ONE; ADENOSINE RECEPTOR BLOCKING AGENT; ALDEHYDE OXIDASE; DRUG METABOLITE; FK 3453; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; PREDICTION; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SPECIES DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ALDEHYDE OXIDASE; ANIMALS; CHILD, PRESCHOOL; HEPATOCYTES; HUMANS; MALE; MICE; PREDICTIVE VALUE OF TESTS; PROTEIN BINDING; PYRIDAZINES; PYRIMIDINES; RADIATION CHIMERA; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 84455171514     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.041954     Document Type: Article

References (36)

1. Akabane T, Tanaka K, Irie M, Terashita S, and Teramura T (2011) Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. Xenobiotica 41:372-384.
2. Beedham C (1987) Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity. Prog Med Chem 24:85-127.
3. Beedham C (1997) The role of non-P450 enzymes in drug oxidation. Pharm World Sci 19:255-263. Review.
4. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
5. Dalvie D, Zhang C, Chen W, Smolarek T, Obach RS, and Loi CM (2010) Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences. Drug Metab Dispos 38:641-654.
6. Diamond S, Boer J, Maduskuie TP Jr, Falahatpisheh N, Li Y, and Yeleswaram S (2010) Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38:1277-1285.
7. Emoto K, Tateno C, Hino H, Amano H, Imaoka Y, Asahina K, Asahara T, and Yoshizato K (2005) Efficient in vivo xenogeneic retroviral vector-mediated gene transduction into human hepatocytes. Hum Gene Ther 16:1168-1174. (Pubitemid 41443709)
8. Garattini E, Mendel R, Romão MJ, Wright R, and Terao M (2003) Mammalian molybdoflavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Biochem J 372:15-32. (Pubitemid 36609603)
9. Garattini E, Fratelli M, and Terao M (2009) The mammalian aldehyde oxidase gene family. Hum Genomics 4:119-130.
10. Garattini E and Terao M (2011) Increasing recognition of the importance of aldehyde oxidase in drug development and discovery. Drug Metab Rev 43:374-386.
11. Guo X, Lerner-Tung M, Chen HX, Chang CN, Zhu JL, Chang CP, Pizzorno G, Lin TS, and Cheng YC (1995) 5-Fluoro-2-pyrimidinone, a liver aldehyde oxidase-activated prodrug of 5-fluorouracil. Biochem Pharmacol 49:1111-1116.
12. Kamimura H, Nakada N, Suzuki K, Mera A, Souda K, Murakami Y, Tanaka K, Iwatsubo T, Kawamura A, and Usui T (2010) Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab Pharmacokinet 25:223-235. Review.
13. Katoh M, Matsui T, Nakajima M, Tateno C, Kataoka M, Soeno Y, Horie T, Iwasaki K, Yoshizato K, and Yokoi T (2004) Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 32:1402-1410. (Pubitemid 39564560)
14. Katoh M, Matsui T, Okumura H, Nakajima M, Nishimura M, Naito S, Tateno C, Yoshizato K, and Yokoi T (2005) Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 33:1333-1340. (Pubitemid 41196976)
15. Kawashima K, Hosoi K, Naruke T, Shiba T, Kitamura M, and Watabe T (1999) Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Metab Dispos 27:422-428. (Pubitemid 29114253)
16. Kitamura S, Sugihara K, Nakatani K, Ohta S, Ohhara T, Ninomiya S, Green CE, and Tyson CA (1999) Variation of hepatic methotrexate 7-hydroxylase activity in animals and humans. IUBMB Life 48:607-611. (Pubitemid 30043806)
17. Kitamura S, Sugihara K, and Ohta S (2006) Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83-98.
18. 1- methylnicotinamide in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 36:1202-1205.
19. Klecker RW, Cysyk RL, and Collins JM (2006) Zebularine metabolism by aldehyde oxidase in hepatic cytosol from humans, monkeys, dogs, rats, and mice: influence of sex and inhibitors. Bioorg Med Chem 14:62-66. (Pubitemid 41635468)
20. Kola I and Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715. (Pubitemid 39173511)
21. 3H-warfarin using chimeric mice with humanized liver. Drug Metab Pharmacokinet 24:153-160.
22. Itoh K, Maruyama H, Adachi M, Hoshino K, Watanabe N, and Tanaka Y (2007) Lack of dimer formation ability in rat strains with low aldehyde oxidase activity. Xenobiotica 37:709-716 (Pubitemid 47057125)
23. Lake BG, Ball SE, Kao J, Renwick AB, Price RJ, and Scatina JA (2002) Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica 32:835-847. (Pubitemid 35155519)
24. Moriyasu A, Sugihara K, Nakatani K, Ohta S, and Kitamura S (2006) In vivo-in vitro relationship of methotrexate 7-hydroxylation by aldehyde oxidase in four different strain rats. Drug Metab Pharmacokinet 21:485-491.
25. Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, and Tran TD (2010) Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53:8441-8460.
26. +/+)/SCID mouse model with a humanized liver for prediction of human metabolism. Xenobiotica 41:464-475.
27. Sugihara K, Tayama Y, Shimomiya K, Yoshimoto D, Ohta S, and Kitamura S (2006) Estimation of aldehyde oxidase activity in vivo from conversion ratio of N1-methylnicotinamide to pyridones, and intraspecies variation of the enzyme activity in rats. Drug Metab Dispos 34:208-212. (Pubitemid 43145022)
28. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, et al. (2004) Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901-912. (Pubitemid 39129297)
29. Terao M, Kurosaki M, Barzago MM, Fratelli M, Bagnati R, Bastone A, Giudice C, Scanziani E, Mancuso A, Tiveron C, et al. (2009) Role of the molybdoflavoenzyme aldehyde oxidase homolog 2 in the biosynthesis of retinoic acid: generation and characterization of a knockout mouse. Mol Cell Biol 29:357-377.
30. Rashidi MR, Smith JA, Clarke SE, and Beedham C (1997) In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Dispos 25:805-813. (Pubitemid 27318599)
31. Rashidi MR, Beedham C, Smith JS, and Davaran S (2007) In vitro study of 6-mercaptopurine oxidation catalysed by aldehyde oxidase and xanthine oxidase. Drug Metab Pharmacokinet 22:299-306.
32. Yamasaki C, Kataoka M, Kato Y, Kakuni M, Usuda S, Ohzone Y, Matsuda S, Adachi Y, Ninomiya S, Itamoto T, et al. (2010) In vitro evaluation of cytochrome P450 and glucuronidation activities in hepatocytes isolated from liver-humanized mice. Drug Metab Pharmacokinet 25:539-550.
33. Yamazaki H, Kuribayashi S, Inoue T, Tateno C, Nishikura Y, Oofusa K, Harada D, Naito S, Horie T, and Ohta S (2010) Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry. Chem Res Toxicol 23:152-158.
34. Yoshitsugu H, Nishimura M, Tateno C, Kataoka M, Takahashi E, Soeno Y, Yoshizato K, Yokoi T, and Naito S (2006) Evaluation of human CYP1A2 and CYP3A4 mRNA expression in hepatocytes from chimeric mice with humanized liver. Drug Metab Pharmacokinet 21:465-474.
35. Zhang X, Liu HH, Weller P, Zheng M, Tao W, Wang J, Liao G, Monshouwer M, and Peltz G (2011) In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor. Pharmacogenomics J 11:15-24.
36. Zientek M, Jiang Y, Youdim K, and Obach RS (2010) In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos 38:1322-1327.